In the article, “Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling” by Macdonald, et al which published online ahead of print on March 8, 2012, the following corrections are needed:
The correct Disclosures are listed below and the changes have been made to the online and print version of the article.
Dr Macdonald receives grant support from Actelion Pharmaceuticals Ltd, and is a stockholder of Edge Therapeutics. Drs Macdonald, Higashida, Keller, Mayer, Molyneux, Raabe, Vajkoczy, Wanke, and Kassell are consultants for Actelion Pharmaceuticals Ltd. Dr Keller has been on speakers' bureaus for Zoll Medical, received research grants from Swiss National Science Foundation, and is a stockholder in NeMoDevices. Dr Molyneux has been a consultant for Micrus Endovascular, and receives grant support from the Medical Research Council UK and Cerecyte Coil Trial Micrus Inc. Ms Bach, and Drs Frey, Nowbakht and Roux are employees and stockholders of Actelion Pharmaceuticals Ltd.
In Table 1, the word “women” should be removed from the first row and AcoA has been changed to anterior communicating artey.
- © 2012 American Heart Association, Inc.